Ken Griffin Sarepta Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$93.7 - $141.53 $6.16 Million - $9.3 Million	-65,700 Reduced 16.56%	331,100 $42.9 Million
Q4 2023 Feb 14, 2024	SELL	$67.31 - $124.76 $1.03 Million - $1.91 Million	-15,300 Reduced 3.71%	396,800 $38.3 Million
Q3 2023 Nov 14, 2023	BUY	$102.5 - $123.59 $13.9 Million - $16.8 Million	136,000 Added 49.26%	412,100 $50 Million
Q2 2023 Aug 14, 2023	SELL	$106.4 - $157.19 $22 Million - $32.5 Million	-206,900 Reduced 42.84%	276,100 $31.6 Million
Q1 2023 May 15, 2023	BUY	$117.53 - $155.99 $16.7 Million - $22.2 Million	142,200 Added 41.73%	483,000 $66.6 Million

Q4 2022 Feb 14, 2023	BUY	$100.86 - $132.13 $605,160 - $792,780	6,000 Added 1.79%	340,800 $44.2 Million
Q3 2022 Nov 14, 2022	BUY	$75.71 - $119.24 $14.8 Million - $23.4 Million	196,100 Added 141.38%	334,800 $37 Million

470

79.3M

4.23M

1.21M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $13.8B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.